23rd Nov 2010 15:30
BLOCK LISTING SIX MONTHLY RETURN
23 November 2010 - Shire plc
Name of applicant: Shire plc Name of scheme: 1996 Executive Share Option Scheme Period of return: From: 23 May 2010 To: 22 November 2010
Balance of unallotted securities under 81,000 scheme(s) from previous return: Plus: The amount by which the block Nil scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/ 2,403 allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not 78,597 yet issued/allotted at end of period:
Name of applicant: Shire plc Name of scheme: 2000 Executive Share Option Scheme Period of return: From: 23 May 2010 To: 22 November 2010
Balance of unallotted securities under 3,891,197 scheme(s) from previous return: Plus: The amount by which the block Nil scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/ 76,320 allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not 3,814,877 yet issued/allotted at end of period:
Name of applicant: Shire plc Name of scheme: Shire Sharesave Scheme Period of return: From: 23 May 2010 To: 22 November 2010
Balance of unallotted securities under 5,392 scheme(s) from previous return: Plus: The amount by which the block Nil scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/ Nil allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not 5,392 yet issued/allotted at end of period:
Name of applicant: Shire plc Name of scheme: Biochem Pharma Stock Option Plan Period of return: From: 23 May 2010 To: 22 November 2010
Balance of unallotted securities under 5,359 scheme(s) from previous return: Plus: The amount by which the block Nil scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/ 1,486 allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not 3,873 yet issued/allotted at end of period:
Name of contact: Tony Guthrie, Deputy Company Secretary Address of contact: Hampshire International Business Park Basingstoke, Hampshire, RG24 8EP
Telephone number of contact: 01256 894754
For further information please contact:
Investor Relations Eric Rojas [email protected] +1 781 482 0999 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
2Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release
www.shire.com
vendorRelated Shares:
Shire